GALVmed has officially launched its new 5-year programme, Veterinary Innovations Transforming Animal health & Livelihoods (VITAL 2) in Nigeria and Kenya. The new programme will leverage public and private partnerships to expand livestock vaccine market access, promote innovation, and improve the resilience of livestock-dependent communities.
The programme was presented during two different high-level events in each country, which were attended by government officials, industry leaders, veterinary health professionals and other key stakeholders.
In Nigeria, the programme was introduced during the Nigerian Veterinary Medical Association (NVMA) Congress 2025 held from 27 October to 31 October 2025. The event provided a strategic platform to present the goals and approach of VITAL 2 to an audience of about 1,000 veterinary professionals and stakeholders.
GALVmed’s VITAL 2 information booth at the Nigerian Veterinary Medical Association (NVMA) Congress 2025
In Kenya, the programme was launched during the Ruminant Vaccination Multi-stakeholder Engagement Workshop held in Nairobi on November 15th. This workshop brought together leaders and experts to discuss and align on national-level priorities, including the status of the ruminant vaccination programme and identifying gaps in vaccine delivery and access.
The forum, organised by the Directorate of Veterinary Services (DVS), the Kenya Veterinary Association (KVA), the International Livestock Research Institute (ILRI) and GALVmed, was very well attended, with over 60 participants representing public, private, and development sector stakeholders.
GALVmed’s CEO Dr Lois Muraguri emphasised the importance of collaboration to raise the national vaccination rate in Kenya, and how VITAL 2 (which covers Kenya, Nigeria, and Tanzania) will help close the vaccination gap and strengthen livestock value chains.
Members from the Kenya Veterinary Association (KVA) and the Global Alliance for Livestock Veterinary Medicines (GALVmed). Source: TV 47
The two conferences highlighted the critical role that effective vaccination plays in improving animal health, productivity, and livelihoods. The launches also provided a platform to outline VITAL 2 objectives, discuss implementation strategies, and reaffirm the shared commitment to supporting small-scale livestock producers.
The introduction of VITAL 2 in Nigeria and Kenya marks a significant step forward in improving access to high-quality, affordable ruminant vaccines across sub-Saharan Africa, further adding to GALVmed’s mission to enhance people livelihoods through livestock health.